22 results about "Hyperkalemia" patented technology

The invention discloses a treatment guidance system for a hyperkalemia patient, and the system comprises a data detection unit which obtains the medical history, symptom signs and inspection data of the patient through the butt joint of a hospital information system and a laboratory information system, and carries out the data cleaning and structural processing; the decision analysis unit is used for generating a first treatment scheme based on a pre-stored treatment guide rule base and the real-time data; the scheme guidance unit is used for generating a second treatment scheme according to the feedback of the auditing end and pushing the second treatment scheme to the execution end; the dynamic monitoring unit is used for monitoring indexes such as blood potassium, blood gas, electrocardiogram, blood sugar and urine volume of the patient in real time and triggering treatment adjustment and reexamination reminding according to a preset rule; and the long-term management unit is used for generating a personalized long-term management scheme in combination with etiological analysis. According to the invention, through standardized treatment process, intelligent dose correction, dynamic risk early warning and multi-department cooperation, precise, continuous and closed-loop management of hyperkalemia treatment is realized, the short-term death rate is reduced, and the long-term prognosis of a patient is improved.

The present disclosure provides systems and methods for detection of hyperkalemia from Lead I electrocardiogram (ECG) signals, particularly in patients with critically high potassium levels. The methods and systems of the disclosure are further demonstrated to identifying hyperkalemia across both acute kidney disease (AKD) and chronic kidney disease (CKD) patient groups, with performance varying according to serum potassium levels.

The invention relates to the technical field, in particular to a dialysate supply system of a hemodialysis machine, which comprises a concentrated solution supply module, a dialysate mixing module, a concentration detection module, a data storage module, an intelligent control module and a centralized control module, the real-time state of a patient is dynamically analyzed through deep learning, components of dialysate are automatically adjusted, the crossing from a fixed formula to individualized dynamic supply is achieved, and the treatment effect is remarkably improved; secondly, the system can predict the risks of hypotension, hyperkalemia and the like prospectively, and actively intervene in advance, so that the incidence rate of dialysis-related acute complications is reduced; and moreover, the workload of medical staff for frequently and manually adjusting parameters is greatly reduced through automatic intelligent control, so that the medical staff can concentrate on clinical decisions, and medical resource allocation is optimized.

The invention relates to the technical field of drugs for treating diabetic nephropathy, and particularly discloses a pharmaceutical composition for treating diabetes mellitus complicated with nephropathy and application. The invention provides a pharmaceutical composition for treating diabetes mellitus complicated with nephropathy. The pharmaceutical composition comprises fenerenone and a potassium-excreting diuretic in a mass ratio of (1-4): (1-10), the potassium-excreting diuretic is selected from at least one of thiazine diuretic, thiazine-like diuretic or loop diuretic. According to the pharmaceutical composition for treating diabetes mellitus complicated with nephropathy provided by the invention, the fenerenone and the potassium-excreting diuretic in a specific ratio are adopted, and in the process of using the fenerenone to treat and control the progress of chronic kidney diseases, the potassium-excreting diuretic which is compounded and combined not only reduces the occurrence of adverse reactions of hyperkalemia, but also enhances the effect of reducing urine protein, so that the curative effect of treating diabetes mellitus complicated with nephropathy is enhanced, and the curative effect of treating diabetes mellitus complicated with nephropathy is improved. Good market application values are realized.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO3−), sulfuric acid group (—OSO3−), carboxylic group (—CO2−), phosphonic acid group (—OPO32−), phosphate group (—OPO32−), and sulfamic acid group (—NHSO3−). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and / or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention provides compounds of Formula (I) or salts thereof: (Formula (I)) wherein X, L, V, R1, R2, R3 and R4 are as defined herein. The claimed compounds inhibit the enzyme type 2 11-hydroxysteroid dehydrogenase (11-HSD2) and thus stimulate potassium excretion by preventing cortisol from being oxidized to corticosterone and thus making it occupy the mineralocorticoid receptor, and are useful in the treatment of hyperkalemia. # imgabs0 #

The present invention provides a compound of formula (I) or a salt thereof: (Formula (I)) wherein X, L, V, R1, R2, R3 and R4 are as defined herein. The claimed compounds inhibit the enzyme type 2 11-hydroxysteroid dehydrogenase (11-HSD2) and are therefore useful for treating hyperkalemia by preventing cortisol from being oxidized to corticosterone and thereby allowing it to occupy the mineralocorticoid receptor, thereby stimulating potassium excretion. #imgabs0#

Compositions and methods are provided for treating first, second degree burns to rapidly minimize hyperkalemia, hyponatremia, blistering, and pain management by externally applying gel mixture on unopened injured burn areas from onset of burn shock. The substrate is a gel mixture matrix containing concentrated sodium ion that creates a concentration gradient, allowing in situ diffusion of sodium ion (in vitro) into blister, edema, and extracellular fluids (in vivo) to reduce hyponatremia and (in situ), delivering the pH control constituents in vivo to prevent initial acidosis, followed by minimizing subsequent alkalosis and normalizing SID while simultaneously in situ expelling potassium ions in vitro from the same fluids transdermally while restoring normal homeostasis. The in situ restoration of homeostasis and electrophysiology also brings pain relief and retards transcapillary vascular fluid loss to help defend kidney and cardiac functions by rectifying transmembrane potential across skeletal, neural, cardiac, and renal cell membranes.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

The present invention relates to a method for preventing or treating hyperkalemia in a subject. The method comprises a first-stage dosing regimen in which poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt is orally administered to the subject 3 times a day, 3 g to 48 g each time, for 2 consecutive days. Optionally, the method comprises a second-stage dosing regimen in which 3 g to 48 g of poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt is orally administered to the subject once a day or once every other day.

The present disclosure provides systems and methods for detection of hyperkalemia from Lead I electrocardiogram (ECG) signals, particularly in patients with critically high potassium levels. The methods and systems of the disclosure are further demonstrated to identifying hyperkalemia across both acute kidney disease (AKD) and chronic kidney disease (CKD) patient groups, with performance varying according to serum potassium levels.

Provided herein are potassium-binding polymers prepared by a polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is a compound of Formula (V), the crosslinking agent is a compound of Formula (VI) and / or a compound of Formula (VII), wherein the variables are as defined in the specification; the present application relates to their use in the treatment or prevention of hyperkalemia.

The present invention is directed to cross-linked cation exchange polymers comprising a fluorine group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such a polymer. Cross-linked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield strength, compressibility, surface morphology, and / or swelling ratio are also described. These polymers and compositions are useful for binding potassium in the gastrointestinal tract.

This disclosure pertains to the field of medicinal chemistry and relates to pharmaceutical polymers for the treatment of hyperkalemia and methods for their preparation. Specifically, this document provides potassium-binding polymers prepared by polymerization of monomers and crosslinking agents, wherein the monomers are compounds of formula (V), and the crosslinking agents are compounds of formula (VI) and / or formula (VII), wherein the variables are as defined in this specification; this application relates to their use in the treatment or prevention of hyperkalemia.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for preventing and treating complications of nephrotic dialysis patients, and a preparation method, a preparation and application thereof. The composition is composed of the following components: whey protein isolate, calcium caseinate and sucralose, and the preparation method of the whey protein isolate comprises the following steps: mixing whey protein concentrate with an ionic liquid, adding an enzyme for hydrolysis, and performing enzyme deactivation to obtain an enzymatic hydrolysate; the enzymatic hydrolysate is sequentially subjected to ultrafiltration and nanofiltration and dried, and the enzyme is a mixture of trypsin and cysteine protease. The concentrated whey protein is subjected to enzymolysis by selecting a specific enzymolysis process to obtain the separated whey protein, and the separated whey protein, the calcium caseinate and the sucralose jointly form the composition for preventing and treating the complications of the nephropathy dialysis patients, so that the composition for preventing and treating the complications of the nephropathy dialysis patients can comprehensively improve the complications of protein malnutrition, hyperphosphatemia, hyperkalemia and the like which are easy to occur in the nephropathy dialysis patients, and has a good clinical application prospect. The occurrence rate of complications of nephropathy dialysis patients is obviously reduced.

To provide a method for treating disease.SOLUTION: The present invention provides a compound of formula (I) or a salt thereof [where X, L, V, R1, R2, R3 and R4 are as defined herein]. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used to treat hyperkalemia.SELECTED DRAWING: Figure 1

The present invention relates to a dry suspension comprising poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt, a suspending agent, and silicon dioxide or a solid powder flavor, and a preparation method therefor; the present invention further relates to the use of the dry suspension in the treatment of hyperkalemia.

The invention discloses a novel application of a traditional Chinese medicine composition and fenerenone in clinically treating diabetic nephropathy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-60 parts of abelmoschus manihot flowers, 5-30 parts of tripterygium hypoglaucum roots, 20-60 parts of astragalus membranaceus and 5-20 parts of wine-prepared fructus corni. The combined use of the traditional Chinese medicine composition and the fenerenone has the attenuated synergistic effects of relieving proteinuria, protecting the renal function, relieving clinical symptoms, improving the side effect of fenerenone hyperkalemia and the like on patients with clinical proteinuria diabetic nephropathy; clinical application proves that the traditional Chinese medicine composition has a better treatment effect on diabetic nephropathy compared with fenerenone, and is higher in safety.

The present invention relates generally to methods of treating hypertension (HTN) in a patient in need thereof, wherein the patient optionally also has chronic kidney disease (CKD) or type II diabetes mellitus (T2DM). The present invention also relates to a method of treating hyperkalemia in a patient in need thereof, wherein the patient has CKD, T2DM, or HTN and is optionally treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The present invention also relates to methods of treating nephropathy in a patient in need thereof, wherein the patient is optionally treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods may include administering to the patient an effective amount of a potassium binding agent to reduce blood pressure and / or enhance or stabilize renal function in the patient.